Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Einhorn v. AxoGen, Inc. et al
Case Number:
8:19-cv-00069
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- DLA Piper
- Glancy Prongay
- Goodwin Procter
- Grant & Eisenhofer
- Pomerantz LLP
- Saxena White
- Trenam Law
- Vianale & Vianale
Companies
- AxoGen Inc.
- Cantor Fitzgerald
- Cantor Fitzgerald LP
- Jefferies Financial Group Inc.
- JMP Group Inc.
- William Blair & Co. LLC
Sectors & Industries:
-
March 22, 2021
Axogen Stock Offering Suit Axed Again, But Appeal Looms
A Florida federal judge has tossed a proposed shareholders' class action against nerve repair product manufacturer Axogen Inc. for a second time, but noted in his order that investors did not seek leave to further amend their complaint because of their stated intent to appeal the case as argued.
-
February 25, 2021
Investors Maintain Nerve Repair Co. Axogen Lied In SEC Docs
Investors urged a Florida federal judge Thursday to let them pursue their claim that nerve repair product manufacturer Axogen lied in stock offering materials, saying they have bolstered proof of the falsehoods and the company's bad faith intentions since the court dismissed a prior version of their complaint.
-
September 21, 2020
Nerve Repair Co. Didn't Even Read Claims, Investor Says
Nerve repair product manufacturer Axogen's bid to toss an amended complaint alleging the company lied about its success and business practices belied a failure to actually read the new claims leveled against it, a pension fund argued in Florida federal court.
-
April 22, 2020
Nerve Repair Co. Axogen Beats Stock-Drop Suit
A Florida federal judge has tossed a stock-drop suit from a proposed class of investors alleging Axogen Inc., a maker of nerve repair products, lied about its success and business practices, ruling the amended complaint was inadequately pled while leaving the door open for it to be amended again.
-
July 23, 2019
Nerve Repair Co. Says Stock-Drop Suit Relies On Iffy Sources
Axogen Inc., a maker of nerve repair products, urged a Florida federal court Monday to toss a stock-drop suit alleging the company lied about its success and business practices, saying shareholders' claims are inadequately pled and based on unreliable sources.
-
April 30, 2019
G&E, Saxena White Win Lead In Nerve-Repair Investor Suit
A Detroit pension plan was appointed lead plaintiff while Grant & Eisenhofer PA and Saxena White PA were named co-lead counsel by a Florida federal judge Tuesday in a stock-drop suit accusing human tissue company AxoGen of lying about its success and business practices.
-
March 12, 2019
Glancy Prongay Seeks To Lead Nerve-Repair Co. Investor Suit
Three AxoGen investors asked a Florida federal judge Monday to appoint them lead plaintiffs and name Glancy Prongay & Murray LLP as lead counsel in their proposed class action accusing the company, which focuses on remedies for peripheral nerve damage, of lying about its success and business practices.